For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are available.
Maintenance rucaparib may improves progression-free survival in patients with ovarian cancer.
Clinicals can use mutiple-gene panels to identify mutations to test for breast cancer and ovarian cancer risk.
A recent study has shown that the cancer risks for women with BRCA1 and BRCA2 mutations depend on the extent of the woman’s family history of cancer and the position of the specific fault within the gene.
Expert Ilana Cass, MD, explains the options that women with have when it comes to preventing ovarian cancer.
Communication is key when it comes to discussing genetic information and hereditary cancers with family members.
A recent survey found that women with ovarian cancer are uncertain of what to expect, and experience a gap when communicating with healthcare providers.
More Stage I cancers were diagnosed after the passage of the Affordable Care Act (ACA), also known as Obamacare, within five screenable disease types: colorectal cancer, female breast cancer, cervical cancer, lung cancer, and prostate cancer).
The human papillomavirus (HPV) vaccine has reduced the prevalence of high-risk oral HPV infections by 88& in young adults that have had at least 1 dose of the vaccine.
A recent analysis showed that many women within the recommended age for routine screening are not up to date on Pap tests.
A recent study has found correlations between common comorbidities (hypertension, heart disease, diabetes, etc) and ovarian cancer.
For BRCA1/2 and other genes, it is important that practitioners begin testing for heriditary genes for ovarian cancers.
As prevalence of HPV within the population rises, incidence of HPV-related cancers is expected to rise.
Fewer people are dying from cancer than years ago, according to a recent study.
The FDA has granted approval for the PARP inhibitor niraparib for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial repsponse to platinum-based chemotherapy.
For patients with BRCA+ ovarian cancer, olaparib in the maintenance setting has shown impressive progression free survival benefits.
When we, as navigators, wake up each morning, we never know what we will be asked to accomplish in the care of our patients and their families.
The risk of dying from cervical cancer appears to be much higher than previously thought, and racial disparities have been greatly underestimated.
According to a recent survey, the main causes for a lack of HPV vaccine uptake are a lack of knowledge and a failure by healthcare providers to recommend it.
After chemotherapy proved unsuccessful, one patient entered a clinical trial of a new combination for immunotherapy for her ovarian cancer.
A multidisciplinary team went to Botswana to bring more effective treatment to patients with cervical cancer.
Survivors of endometrial cancer are at higher risk for long-term cardiovascular problems such as phlebitis, thrombophlebitis, pulmonary heart disease, hypotension and atrial fibrillation.
In a current phase II/III clinical trial for patients with advanced, recurrent, platinum-resistant ovarian cancer, the novel agent fasbretablin tromethamine is combined with bevacizumab (Avastin) and either paclitaxel or pegylated liposomal doxorubicin.
A recent study suggested that intentional weight loss could decrease the risk of endometrial cancer.
Gynecologic oncology and reproductive medicine expert discusses the new HPV vaccine recommendations and the importance of awareness for all HPV-caused cancers.
